Cargando…
Manufacturing of Recombinant Human Follicle-Stimulating Hormone Ovaleap(®) (XM17), Comparability with Gonal-f(®), and Performance/Consistency
Ovaleap(®) (XM17) is a recombinant human follicle-stimulating hormone to treat infertility by inducing ovulation or controlled ovarian stimulation for assisted reproductive technology (ART) procedures. Ovaleap(®) (follitropin-α) was approved by the European Medicines Agency in 2013 as a biosimilar m...
Autores principales: | Winstel, Rainer, Wieland, Juergen, Gertz, Beate, Mueller, Arnd, Allgaier, Hermann |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427053/ https://www.ncbi.nlm.nih.gov/pubmed/28386738 http://dx.doi.org/10.1007/s40268-017-0182-z |
Ejemplares similares
-
Phase I, two-way, crossover study to demonstrate bioequivalence and to compare safety and tolerability of single-dose XM17 vs Gonal-f(®) in healthy women after follicle-stimulating hormone downregulation
por: Lammerich, Andreas, et al.
Publicado: (2015) -
Phase 1 safety, tolerability, and pharmacokinetic study of single ascending doses of XM17 (recombinant human follicle-stimulating hormone) in downregulated healthy women
por: Lammerich, Andreas, et al.
Publicado: (2015) -
Randomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap® (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART)
por: Strowitzki, Thomas, et al.
Publicado: (2016) -
Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to Main Study
por: Strowitzki, Thomas, et al.
Publicado: (2016) -
Olivetti OPE XM 5220/2
Publicado: (2017)